IP Library Granted Patent US 10,617,715
Granted Patent B2
US 10,617,715 · App. 12/645,419 · Granted Apr 14, 2020

Methods of treating or preventing biofilm associated infections with free available chlorine free available chlorine water

Inventors: Robert Northey (Petaluma, CA); Eileen Thatcher (Petaluma, CA); Andres Gutierrez (Petaluma, CA)
Assignee: Sonoma Pharmaceuticals, Inc.
A61K33/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,617,715
App. No.
12/645,419
Granted
Apr 14, 2020
Kind
B2
Abstract

The invention provides methods of treating or reducing the incidence of an infection in a mammal due to a biofilm associated infectious microorganism comprising administering a therapeutically effective amount of free available chlorine (FAC) water to a site populated with biofilm associated infectious microorganism.

Claims (27)

1. A method of treating or reducing the incidence of inflammation associated with a biofilm containing an infectious microorganism on an oral mucosal tissue in the oral cavity of a mammal, the method comprising disaggregating the biofilm by contacting the biofilm on the oral mucosal tissue with a therapeutically effective amount of free available chlorine (FAC) water for at least about 30 minutes, wherein:

(a) the pH of the FAC water is from about 7.3 to about 7.5,

(b) the concentration of oxychlorine species in the FAC water is 150 mg/L to 200 mg/L, and

(c) the infectious microorganism is selected from Pseudomonas sp., Haemophilus sp., Pneumococcus sp., Mycobacterium sp., Stenotrophomonas sp., Streptococcus sp., Escherichia sp., Mycoplasma sp., and combinations thereof,

to treat or reduce the incidence of the inflammation associated with the biofilm.

2. The method of claim 1 , wherein the infectious microorganism is in a preinfectious commensal state.

3. The method of claim 1 , wherein the mammal is a human patient.

4. The method of claim 3 , wherein the mammal has an immunodeficiency.

5. The method of claim 3 , wherein the FAC water is administered as a lavage, drop, rinse, spray, mist, aerosol, steam or combination thereof.

6. The method of claim 3 , wherein the FAC water is administered in the form of droplets having a diameter in the range of from about 0.1 micron to about 100 microns.

7. The method of claim 3 , further comprising administering at least one antibiotic agent.

8. The method of claim 1 , wherein the FAC water is stable for at least about two months.

9. The method of claim 1 , wherein the FAC water comprises a mixture of cathode water and anode water.

10. The method of claim 1 , wherein the oxychlorine species is selected from the group consisting of hypochlorous acid, hypochlorite ions, sodium hypochlorite, and mixtures thereof.

11. The method of claim 1 , wherein the FAC water reduces the concentration of viable bacteria in the biofilm by at least about 2 logs within 60 minutes.

12. A method of treating or reducing the incidence of inflammation associated with a biofilm containing an infectious microorganism on an oral mucosal tissue in the oral cavity of a mammal, the method comprising disaggregating the biofilm by contacting the biofilm with a therapeutically effective amount of free available chlorine (FAC) water for at least about 30 minutes, wherein:

(a) the pH of the FAC water is from about 7.3 to about 7.5,

(b) the concentration of oxychlorine species in the FAC water is 150 mg/L to 200 mg/L, and

(c) the infectious microorganism is selected from Pseudomonas sp., Haemophilus sp., Pneumococcus sp., Mycobacterium sp., Stenotrophomonas sp., Streptococcus sp., Escherichia sp., Mycoplasma sp., and combinations thereof,

to treat or reduce the incidence of the inflammation associated with the biofilm, and

wherein the method further comprises administering to the mammal at least one antibiotic agent.

13. The method of claim 12 , wherein the infectious microorganism is in a preinfectious commensal state.

14. The method of claim 12 , wherein the mammal is a human patient.

15. The method of claim 12 , wherein the FAC water is stable for at least about two months.

16. The method of claim 12 , wherein the FAC water comprises a mixture of cathode water and anode water.

17. The method of claim 12 , wherein the oxychlorine species is selected from the group consisting of hypochlorous acid, hypochlorite ions, sodium hypochlorite, and mixtures thereof.

18. The method of claim 1 , comprising contacting the biofilm with the FAC water for at least about 60 minutes.

Assignments (6)
CHANGE OF NAME Recorded Jan 5, 2017
From: OCULUS INNOVATIVE SCIENCES, INC.
To: SONOMA PHARMACEUTICALS, INC.
Reel/Frame 041257/0375 →
RELEASE OF LIEN Recorded Feb 24, 2015
From: VENTURE LENDING & LEASING V, INC.
To: OCULUS INNOVATIVE SCIENCES, INC.
Reel/Frame 035090/0111 →
RELEASE OF LIEN Recorded Feb 24, 2015
From: VENTURE LENDING & LEASING VI, INC.
To: OCULUS INNOVATIVE SCIENCES, INC.
Reel/Frame 035090/0143 →
SECURITY INTEREST Recorded Jul 7, 2011
From: OCULUS INNOVATIVE SCIENCES, INC.
To: VENTURE LENDING & LEASING V, INC.
Reel/Frame 026619/0196 →
SECURITY AGREEMENT Recorded Jul 7, 2011
From: OCULUS INNOVATIVE SCIENCES, INC.
To: VENTURE LENDING & LEASING VI, INC.
Reel/Frame 026619/0235 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2010
From: NORTHEY, ROBERT; THATCHER, EILEEN; GUTIERREZ, ANDRES
To: OCULUS INNOVATIVE SCIENCES, INC.
Reel/Frame 024097/0042 →
Continuity (2)
Provisional Application 61139972 · Dec 22, 2008
Related Publication 20100166809A1 · Jul 1, 2010